After the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder, companies are ...

MDMA-assisted psychotherapy has been shown to be a safe and effective treatment for PTSD and complex trauma. Why did the FDA ...

The latest version of ICER’s evidence report (PDF) on Lykos’ MDMA-assisted ... those living with PTSD. The company also said it had sought and received feedback from the FDA throughout the ...

The fallout from the FDA's recent decision not ... involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.

Despite the FDA's Breakthrough Therapy Designation for MM120, the regulatory landscape for psychedelic-based treatments remains complex. Recent setbacks in the approval of MDMA for PTSD treatment ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.